Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
26
05
2021
revised:
19
07
2021
accepted:
24
08
2021
pubmed:
2
9
2021
medline:
24
2
2022
entrez:
1
9
2021
Statut:
ppublish
Résumé
Postmenopausal pregnenolone and/or progesterone levels in relation to endometrial and ovarian cancer risks have been infrequently evaluated. To address this, we utilized a sensitive and reliable assay to quantify prediagnostic levels of seven markers related to endogenous hormone metabolism. Hormones were quantified in baseline serum collected from postmenopausal women in a cohort study nested within the Breast and Bone Follow-up to the Fracture Intervention Trial (B∼FIT). Women using exogenous hormones at baseline (1992-1993) were excluded. Incident endometrial ( Circulating progesterone levels were not associated with endometrial [tertile (T)3 vs. T1 HR (95% confidence interval): 1.87 (0.85-4.11); Using sensitive and reliable assays, this study provides novel data that endogenous progesterone levels are not strongly associated with incident endometrial or ovarian cancer risks. 17-hydroxypregnenolone was positively associated with ovarian cancer and inversely associated with endometrial cancer. While our results require replication in large studies, they provide further support of the hormonal etiology of endometrial and ovarian cancers.
Sections du résumé
BACKGROUND
Postmenopausal pregnenolone and/or progesterone levels in relation to endometrial and ovarian cancer risks have been infrequently evaluated. To address this, we utilized a sensitive and reliable assay to quantify prediagnostic levels of seven markers related to endogenous hormone metabolism.
METHODS
Hormones were quantified in baseline serum collected from postmenopausal women in a cohort study nested within the Breast and Bone Follow-up to the Fracture Intervention Trial (B∼FIT). Women using exogenous hormones at baseline (1992-1993) were excluded. Incident endometrial (
RESULTS
Circulating progesterone levels were not associated with endometrial [tertile (T)3 vs. T1 HR (95% confidence interval): 1.87 (0.85-4.11);
CONCLUSIONS
Using sensitive and reliable assays, this study provides novel data that endogenous progesterone levels are not strongly associated with incident endometrial or ovarian cancer risks. 17-hydroxypregnenolone was positively associated with ovarian cancer and inversely associated with endometrial cancer.
IMPACT
While our results require replication in large studies, they provide further support of the hormonal etiology of endometrial and ovarian cancers.
Identifiants
pubmed: 34465588
pii: 1055-9965.EPI-21-0669
doi: 10.1158/1055-9965.EPI-21-0669
pmc: PMC8568650
mid: NIHMS1737940
doi:
Substances chimiques
Biomarkers
0
Progesterone
4G7DS2Q64Y
Estradiol
4TI98Z838E
Pregnenolone
73R90F7MQ8
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2030-2037Subventions
Organisme : NCI NIH HHS
ID : N02CP11019
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA CP010126
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA CP010128
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Carcinogenesis. 2014 Feb;35(2):346-55
pubmed: 24213602
Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:95-107
pubmed: 32732107
JAMA Netw Open. 2020 Apr 1;3(4):e203645
pubmed: 32329771
Apoptosis. 2021 Apr;26(3-4):184-194
pubmed: 33515314
Obstet Gynecol. 1979 Oct;54(4):521-6
pubmed: 492641
Int J Cancer. 2013 Jan 15;132(2):417-26
pubmed: 22553145
Tumour Biol. 2013 Oct;34(5):2583-7
pubmed: 23609033
Adv Exp Med Biol. 2008;630:148-65
pubmed: 18637490
JNCI Cancer Spectr. 2019 Sep;3(3):pkz029
pubmed: 31321379
Horm Mol Biol Clin Investig. 2015 Sep;23(3):79-84
pubmed: 26353176
Cancer Res. 2000 Feb 15;60(4):936-43
pubmed: 10706108
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1100-1105
pubmed: 33827983
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Chem Biol Interact. 2013 Feb 25;202(1-3):210-7
pubmed: 23200943
Lancet. 2015 May 9;385(9980):1835-42
pubmed: 25684585
JAMA. 1998 Dec 23-30;280(24):2077-82
pubmed: 9875874
Obstet Gynecol. 2018 Jan;131(1):109-116
pubmed: 29215513
Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):648-56
pubmed: 26908437
Am J Epidemiol. 2007 Feb 1;165(3):235-45
pubmed: 17110639
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1081-9
pubmed: 27197275
Endocr Relat Cancer. 2006 Sep;13(3):717-38
pubmed: 16954427
Eur J Biochem. 2000 Jun;267(11):3243-7
pubmed: 10824109
J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
pubmed: 9839517
JAMA. 2006 Dec 27;296(24):2927-38
pubmed: 17190893
Osteoporos Int. 1993;3 Suppl 3:S29-39
pubmed: 8298200
Cancer Causes Control. 2011 Aug;22(8):1075-84
pubmed: 21637986
Int J Cancer. 2019 Oct 15;145(8):2051-2060
pubmed: 30684389
Horm Cancer. 2016 Feb;7(1):49-64
pubmed: 26728471
Brain Struct Funct. 2016 Nov;221(8):3845-3867
pubmed: 26897178
Trends Mol Med. 2013 Mar;19(3):197-209
pubmed: 23348042
Br J Cancer. 2012 Sep 25;107(7):1181-7
pubmed: 22929888
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1419-22
pubmed: 26104910
Lancet. 1996 Dec 7;348(9041):1535-41
pubmed: 8950879
Int J Cancer. 2000 May 1;86(3):436-9
pubmed: 10760835
Obstet Gynecol Clin North Am. 1987 Mar;14(1):299-320
pubmed: 3306523
Br J Cancer. 1988 Feb;57(2):205-12
pubmed: 3358913